The Cancer Control (CC) Program at the Ohio State University Comprehensive Cancer Center (OSUCCC), led by Electra D. Paskett, PhD, MSPH and Mary Ellen Wewers, RN, PHD, MPH, has 52 members from 19 OSU departments within the OSU Colleges of Medicine, Public Health, Arts and Sciences, Law, Nursing, Education and Human Ecology, Dentistry, and Food, Agricultural and Environmental Sciences, as well as Nationwide Children's Hospital and Cincinnati Children's Hospital. Program members provide a wealth of behavioral, basic, clinical, policy, outcomes, and social scientific knowledge and expertise not only to the CC Program, but to the OSUCCC as a whole. The overall CC Program goal is to conduct research to reduce the incidence, mortality and morbidity of cancer, which is accomplished by employing a transdisciplinary research team approach.
The Specific Aims of the CC Program are to: 1) Identify molecular, genetic, and behavioral factors related to cancer incidence and mortality; 2) Develop and test behavioral interventions to prevent or detect cancer early; and, 3) Assess and intervene on issues of cancer survivorship. An additional developing aim of the CC Program is to address policy in relation to cancer prevention, detection, and care. Within these aims, research focuses on cross-cutting themes including underserved/minority populations within our catchment area, communication research, tobacco use and toxicity (including regulatory science), and behavioral strategies that capitalize on our members' strengths, such as epidemiology, biology and behavior. The program now has 2 NCI P50-funded Centers, both showcasing not only our multi-level focus but also the transition from observational to interventional studies. In addition, many of our interventions, e.g., Patient Navigation and Bio-Behavioral Intervention to Reduce Stress after Breast Cancer, have been incorporated into clinical care. Moreover, our research has contributed to policy changes, most notably the establishment of a smoke-free campus at OSU. During this past funding period (2009 - 2014), the Program members published a total 611 articles in peer-reviewed journals of which 32% have intra-programmatic collaboration, 20% have inter-programmatic collaborations, and 404 (66%) of the publications represent multi-institutional collaborations. Many of these publications fall within each of these categories bringing the total collaborative publications to 85%. CC Program funding stands at $6.8M of which $6.2M is peer-reviewed funding and of that, $3.9M (63%) is NCI funding. CC Program investigators have enrolled 9,205 participants to research studies over the last 5 years, 64% to externally peer-reviewed studies and 34% to institutional studies, 1.2% to cooperative trial group studies and 0.8% to industry studies. Of these, 6,964 (76%) were enrolled on interventional studies and 2,241 (24%) on non-interventional studies. Future goals focus on increasing research in: 1) policy, allowing us to take advantage of health care policy initiatives; 2) molecular and genetic epidemiology and 3) patient outcomes, fostering more inter-programmatic research with clinicians.

Public Health Relevance

OVERALL NARRATIVE The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach. Research conducted within the five OSUCCC Programs focuses on ways to reduce the higher rates of lung, breast, CRC and prostate cancer as well as the higher prevalence of risky behaviors such as lack of screening, obesity, high tobacco use, and lack of HPV vaccine. Outreach efforts through the OSUCCC address the needs of underserved populations - lower education; poor; inner city African American; rural and urban Hispanic; Appalachian; rural; Amish; and Somali - by providing targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, community gardening, and addressing policy issues (eg, tobacco-free campus).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843852
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-09-12
Project End
2020-11-30
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Surgery
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kiss, Daniel L; Baez, William D; Huebner, Kay et al. (2018) Loss of fragile histidine triad (Fhit) protein expression alters the translation of cancer-associated mRNAs. BMC Res Notes 11:178
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Denton, Nicholas L; Chen, Chun-Yu; Hutzen, Brian et al. (2018) Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics 11:62-74
Krasnick, Bradley A; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol 117:363-371
Lehmann, Vicky; Nahata, Leena; Ferrante, Amanda C et al. (2018) Fertility-Related Perceptions and Impact on Romantic Relationships Among Adult Survivors of Childhood Cancer. J Adolesc Young Adult Oncol 7:409-414
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Kohnken, Rebecca; Wen, Jing; Mundy-Bosse, Bethany et al. (2018) Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood 131:771-781
Londhe, Priya; Yu, Peter Y; Ijiri, Yuichi et al. (2018) Classical NF-?B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. Front Oncol 8:104
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Xing, Deyin; Zheng, Gang; Schoolmeester, John Kenneth et al. (2018) Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix. Am J Surg Pathol 42:750-760

Showing the most recent 10 out of 2602 publications